Vivos Therapeutics Inc (VVOS) News

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call...

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]